Analysts Initiate Coverage on Scribe Therapeutics with Price Targets Up to $60 as CRISPR Platform Gains Traction

Multiple firms initiate coverage on Scribe Therapeutics with Buy ratings and targets up to $60 after its IPO, spotlighting CRISPR tech for cholesterol.